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Umbilical cord blood (UCB) is a promising, increasingly used option for allogeneic stem cell 
transplantation. Among the beneficial features are availability, permissiveness regarding human 
leukocyte antigen (HLA)-matching, and low incidences of graft-versus-host disease (GVHD). A great 
disadvantage is the low cell number in the grafts and therefore insufficient T cell numbers to prepare 
for donor lymphocyte infusion (DLI). Expansion of cord blood cells in vitro has been conducted to 
solve this obstacle, and in this paper we present an attempt to optimize the expansion protocol used 
by Okas et al. for expansion of T cells for DLI. By using different culture conditions in five UCB derived 
T cell expansions, the results showed propitious effects of interleukin (IL)-7 and that an IL-2 
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LIST OF ABBREVIATIONS 
 
aGVHD Acute graft-versus-host disease 
AICD Activation-induced cell death 
ALL Acute lymphoid leukaemia 
AML Acute myeloid leukaemia 
ASCT Allogeneic stem cell transplantation 
BM Bone marrow 
BMSCT Bone marrow stem cell 
 transplantation 
BMT Bone marrow transplantation 
CB Cord blood 
CBU Cord blood unit 
CD Cluster of differentiation 
cGVHD Chronic graft-versus-host disease 
CLL Chronic lymphoid leukaemia 
CML Chronic myeloid leukaemia 
DLI Donor lymphocyte infusion 
EFS Event-free survival 
FACS Fluorescence-activated cell sorting 
FasL Fas ligand 
FasR Fas receptor 
GVHD Graft-versus-host disease 
GVL Graft-versus-leukaemia 
HD Hodgkin’s disease 
HLA Human leukocyte antigen 
HSC Haematopoietic stem cell 




MDS Myelodysplastic syndrome 
MM Multiple myeloma 
MNC Mononuclear cell 
NC Nucleated cells 
NHL Non-Hodgkin’s lymphoma 
NMC Non-myeloablative conditioning 
OS Overall survival 
PBMC Peripheral blood mononuclear cells 
PCR Polymerase chain reaction 
RCC Renal cell carcinoma 
RIC Reduced intensity conditioning 
SC Stem cell 
SCF Stem cell factor 
SCT Stem cell transplantation 
T cell Thymus-dependant lymphocyte 
Tcm Central memory T cell 
TCR T cell receptor 
Tem Effector memory T cell 
TH1 T helper type 1 
TH2 T helper type 2 
TKI Tyrosine kinase inhibitor 
Tn Naïve T cell 
TNC Total nucleated cells 
Treg Regulatory T cell 
TRM Transplant related mortality 
Ttde Terminally differentiated T cell 
UCB Umbilical cord blood 






1.1. Indications and Stem Cell Sources for Allogeneic Stem Cell 
Transplantations 
Allogeneic stem cell transplantations (ASCTs) have been used as therapy since 1957 (Thomas et al.), 
although reports of use of bone marrow infusions for treatment of anaemia and leukaemia extend to 
late 19th century. It is today a well-established therapy for haematological and oncological diseases. 
Current indications for ASCT include acute myeloid leukaemia (AML), myelodysplastic syndrome 
(MDS), and some acute lymphoid leukaemias (ALLs) in patients with poor response to chemotherapy 
alone. Another, former indication was chronic myeloid leukaemia (CML) until the introduction of 
tyrosine kinase inhibitors (TKI). Now ASCT is administrated only after treatment failure of TKIs. ASCT 
is also used to treat chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), myelofibrosis, 
high-risk lymphomas, Hodgkin’s disease (HD), non-Hodgkin’s lymphoma (NHL). As a more 
experimental approach ASCT have been tried as a treatment modality for some metastatic solid 
tumours, including renal cell carcinoma (RCC), prostatic cancer, carcinoma of the ovaries, breast and 
pancreas, although with variable results. The non-malignant indications include severe aplastic 
anaemia, some haemoglobinopathies and some inborn errors of metabolism and immunodeficiency 
syndromes [1-6].  
The indications for ASCT are constantly evaluated and changed. The introduction of non-
myeloablative conditioning (NMC) or reduced intensity conditioning (RIC) has included older patients 
and patients with co-morbidities that traditionally would be selected out. [7-10] 
Traditionally, the source of stem cells was bone marrow (BM). After the later implementation of 
retrieving haematopoietic stem cells from peripheral blood mononuclear cells (PBMC), the term 
haematopoietic stem cell transplantation (HSCT) was established [11]. Today, PBMCs is the first 
choice as stem cell (SC) source in adults, since no anaesthesia is needed and because of the easy 
availability of more haematopoietic stem cells (HSCs). This is also supported by results showing that 
engraftment, frequency of graft failure, relapse, acute graft-versus-host disease (aGVHD) and survival 
are comparable to BM, although frequency of chronic GVHD (cGVHD) is increased [12-15]. 
For both malignant and non-malignant conditions, the approach to ASCT starts with human leukocyte 
antigen (HLA)-typing of siblings. HLA typing is today performed in a PCR-based manner, with DNA 
sequence-specific typing techniques.  The genotype results are presented in one of two ways; low-
resolution- and high-resolution. Low resolution (2-digit typing) corresponds to the serological typing 
used before, and identifies broad families of alleles, while high-resolution typing (4-digit) identifies 




outcome of SCT and leads to alloimmune responses in either direction, i.e. graft-versus-host or host-
versus-graft, that can lead to GVHD or graft failure, respectively [18]. 
If no HLA-identical sibling is found, the search continues in national and international registries. In 
children with leukaemia who have HLA-identical sibling donors, BM is the first choice as source of 
stem cells, after a retrospective study showed increased occurrence of cGVHD and mortality with the 
use of PBMCs [19]. In about 1/3 of cases, no suitable donor can be found in the stem cell registries 
around the world [20]. 
If no identical unrelated donor can be found, i.e. a 10/10 match (HLA-A, -B, -C, -DRB1, -DQB1 – gold 
standard) or a 6/6 match (HLA-A, -B, -DRB1 - minimum matching level accepted), a mismatched 
donor has to be utilized. Umbilical cord blood (UCB) is a source of HSCs with less stringent demands 
of HLA matching. UCB is increasingly used as a source of stem cells: in 1993 the number of UCB 
transplants (UCBT) was 3 while the number in 2008 was 3 529. The availability of cord blood units 
(CBUs) has increased 10-fold the last 10 years: from 44 000 banked CBUs in 1999 to 452 000 in 2008 
[21]. The current number of banked units is > 470 000 (http://bmdw.org/). 
A 4/6 HLA match has been shown to have comparable results to matched and mismatched (1-2 HLA) 
unrelated BMSCT and also matched sibling donors [22-24]. HLA matching for UCB is defined from low 
resolution for HLA-A and -B and high resolution for HLA-DR.  
It has been, and is still discussed whether HLA-match or cell dose has the greatest impact regarding 
the outcome of UCBT. It has been shown that low cell dose, which often is a problem with UCB, is 
associated with delayed engraftment and increased transplant related mortality (TRM) [25]. Also 
with higher degree of HLA mismatch, the cell dose is of greater importance [26].   
One way to overcome the cell dose problem, which has been employed lately, is the transplantation 
of two UCB-units, partially matched to the recipient and between each other [5, 27, 28].  
The permissiveness of HLA matching of CB units is a feature that has been shown in multiple studies, 
and also that potential mismatch(es) can partly be compensated for with increased cell dose, and 
that cell dose is the most important factor for outcome [29-31]. Other studies argue for HLA 
matching as the main predictor of outcome [32, 33]. Several studies have, however, demonstrated 
and concluded that cell dose is more important than HLA-matching in order to achieve a successful 
transplantation [25, 34-37].  
The study by Gluckman et al. of EUROCORD data concluded that there was a decreased negative 
effect of HLA mismatches when compensated for with a higher cell dose. These findings were evident 
when using grafts with 1-2 HLA mismatches. Patients receiving grafts of 3-4 HLA-mismatches were 
not influenced by increased cell dose [31]. They concluded with the following recommendations of 




1. 6/6 match with cell dose > 3 *107 NC/kg 
2. 5/6 match with cell dose > 4 *107 NC/kg 
3. 4/6 match with cell dose > 5 *107 NC/kg 
The outcomes of UCBT compared to BMT are promising. Multiple studies have shown that 
engraftment after UCBT is delayed, with a longer period of neutropenia and associated increased risk 
of bacterial infections. The prolonged lymphopenia seen after UCBT and the naivety of CB T cells also 
contributes to the increased rate of opportunistic infections seen after UCBT, which is the major 
cause of TRM in the first 6 months post-transplant [38]. However, the current clinical results of UCBT 
compared to BMT, shows comparable results regarding overall survival (OS), event-free survival 
(EFS), incidence of relapse and a similar or decreased risk of GVHD [22-24, 39-43]. 
As mentioned, cord blood grafts have shown to induce GVHD to a less degree, both in incidence and 
severity. This is probably due to a more naïve T cell population, that have been shown to have a 
smaller capacity to produce cytokines [44] and perform lysis, shown by measuring cytotoxic activity 
in mixed leukocyte cultures [45].  
Multiple definitions of T cell subsets have been proposed based on the expression of certain 
molecules. We use the definition that follows: Naïve T cells are cells that have left the thymus and 
not yet met their antigen. They are termed Tn, express CCR7 (a lymph node homing receptor) and do 
not express CD45RO. T cells positive for both, i.e. CCR7+ CD45RO+ are termed central memory T cells 
(Tcm), when they lose their constitutive expression of CCR7 and still are CD45RO+ they are effector 
memory T cells (Tem), while T cells negative for both are terminally differentiated effector T cells 
(Ttde) (Table 1). Tcm compared to Tn cells are less dependent on co-stimulation and are more 
sensitive to antigenic stimuli, while Tcm compared to Tem have little effector function and can easily 
proliferate and differentiate into effectors when stimulated by antigens in secondary lymphoid 
organs and Tem moves out to the inflamed tissues to display their effector functions [46, 47]. 
 










CCR7 + + - - 
CD45RO - + + - 





1.2. Umbilical Cord Blood as Source for ASCT 
The latest established alternative for ASCT is umbilical cord blood (UCB). The first successful cord 
blood transplantation was executed in 1988 by Gluckman et al. in a patient with Fanconi’s anaemia 
who received umbilical cord blood from his sister [48].  
UCB is today most often used when no HLA matched donor is found, since 1-2 HLA mismatches can 
be tolerated with the use of cord blood.  The matching of UCB is currently defined with low 
resolution assays for HLA-A and HLA-B, and high resolution assays for HLA-DR. Because of the 
permissiveness for mismatch, the probability of finding a suitable donor is higher, also for patients 
with uncommon tissue types. In 99% a 4/6 match will be found and in 70% a 5/6 or 6/6 match [49]. 
Other features that favours UCB as a stem cell source is its availability; the product is frozen and 
ready to be thawed and used, it has been HLA typed, serological status for multiple viruses and other 
infectious agents is known and the number of total nucleated cells (TNCs) has been established. 
 
1.3. T Lymphocytes 
Donor lymphocyte infusion (DLI) has been used as adoptive immunotherapy for threatening 
malignancy relapse, graft failure, and post-transplant infections after SCT [50-53]. T cells are 
responsible for the majority of the graft-versus-leukaemia (GVL)-effect seen after ASCT. This has 
been supported by the observed effect of administration of DLI after transplantation, where 
eradication of relapsing malignancy can be achieved [52, 54-56]. DLI can also induce GVHD in as 
much as 50 % of patients receiving DLI. It is still not possible to segregate GVHD from the GVL effect. 
For UCB-transplants, DLI has not been a possibility for logistical and ethical reasons. To overcome this 
obstacle, expansion of T cells in vitro from the cord blood graft has been conducted. At the time of 
cord blood sampling, approximately 5% of the graft has been taken out for the possibility of 
expansion of T cells in vitro. GVL effect, its association with GVHD, and T cells as the main effectors of 
the response, have been advocated for through results that showed lower relapse rates in patients 
who developed GVHD [57]. Also, the higher risk of relapse seen in patients receiving syngeneic 
transplants compared to matched sibling donors [58, 59] and the increased relapse rates in patients 
receiving T cell depleted grafts [60] has supported this.  
Ex vivo expansions of T lymphocytes have been described with procedures using anti-CD3/-CD28 
beads and interleukin (IL)-2, originally developed for expansions of T lymphocytes from PBMC [61-
63]. Other protocols, including the use of IL-7, anti-CD3, IFN-ɣ, IL-12, IL-4, Stem cell factor (SCF) have 




1.4. IL-2 and IL-7: Two Members of the ɣc Family Cytokines 
The ɣc family cytokines consists of the interleukins IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. They share the 
ɣc component of their receptors, also known as IL-2Rɣ and CD132 [68-74]. The sharing of receptor 
components is a part of a complicated system of overlapping effects and cross-regulation between 
these cytokines (reviewed in [75]).   
Most of these cytokines are produced by cells of the immune system after different stimuli, while IL-
7 and IL-15 are constitutively produced by stromal and epithelial cells in bone marrow and thymus 
and by fibroblastic reticular cells in the T cell zones of secondary lymphoid organs [76, 77].  
IL-7 is of uttermost importance in the regulation of naïve and memory T cell homeostasis [78-81]. 
Since IL-7 is constitutively produced, its effects are regulated through the expression of IL-7Rα, that is 
expressed by naïve and memory cells, and down regulated after activation through TCR, and by IL-7 
itself, IL-2, and other cytokines with pro-survival properties  [78, 82-84]. This supports the 
homeostatic properties of IL-7 in that it leaves more of the continuous IL-7-pool for cells that have 
not received a signal for survival and increases the availability of the cytokine for these [84]. Direct 
effects of IL-7 signalling on T cells are promotion of survival through pro-survival PI3-kinase-AKT 
signalling pathway and increased expression of several survival factors and inhibition of pro-
apoptotic factors expression[76, 85]. In addition IL-7 also induces proliferation of memory T cells in 
physiological conditions and memory- and naïve T cells under lymphopenic conditions. [78, 79, 86, 
87] 
IL-2 is a cytokine with many functions. The IL-2 receptor (IL-2R) has three subunits, IL-2Rα, IL-2Rβ and 
the ɣc. They form the high-affinity IL-2 receptor. Low-affinity and intermediate-affinity versions exist 
in other combinations of the subunits [88, 89]. IL-2 induce T cell proliferation and differentiation 
(reviewed in [90]) and is involved in the formation of regulatory T cells (Treg). Although IL-2 is one of 
the main products of TH1 cells [91], it is required for induction of differentiation into TH2 cells through 
an increased responsiveness to IL-4 by promoting expression of the IL-4Rα [92]. Summarized, IL-2 is 
immunostimulatory to T cells in the following ways: support of T cell proliferation [93-98], support of 




We wanted to improve the method used for T cell expansion of UCB T cells by Okas et al. [103] by 




2. MATERIAL AND METHODS 
2.1. Antibodies and Reagents 
Fluorescein isothiocyanate (FITC)-labeled anti-CD3, phycoerythrin (PE)-stained Annexin V, 7-AAD 
(both from BD Pharmingen apoptosis detection kit), PE-anti-CD3, PE-Cy7-anti-CCR7, PE-Cy5-anti-
CD95, PE-Cy5-anti-CD3, PE-Texas Red-anti-CD4, allophycocyanin (APC)-labeled anti-CD45RO, APC-
anti-CD4, APC-Cy7-anti-CD8 (BD, Pharmingen, USA). 
CD3/CD28 beads (Dynabeads ClinExVivo, Invitrogen Dynal AS, Oslo, Norway), CliniMACS phosphate 
buffered saline (PBS)/ethylene diamine tetra-acetaten (EDTA) buffer (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany), Lymphoprep (Fresenius Kabi Norge AS), DMSO and RPMI 1640 (SigmaAldrich, 
Germany). 
 
2.2. Expansion of Cord Blood-Derived T Cells 
Five cord blood units were received from the maternity ward on Karolinska University Hospital 
Huddinge, Stockholm.  
The method described by Okas et al. for clinical expansion has been used as a basis [103]. 
Before freezing, the cord blood was diluted 1:1 with PBS and the CB mononuclear cells (MNC) were 
separated using density gradient centrifugation in Lymphoprep. MNC were pipetted off and washed 
3x in PBS. After counting, the cells were frozen in RPMI 1640-medium with 10 % DMSO, to inhibit 
forming of ice crystals. 
The day of thawing and washing of cells, termed day 0 of the expansion, a 5 % aliquot of the CB unit 
were thawed and washed once in RPMI 1640 medium and thereafter once in PBS/EDTA buffer. 
Further the cells were counted and re-suspended in PBS buffer with the same amount of anti-CD3/-
CD28 magnetic beads (after they were washed x1 in PBS to remove detached antibodies) as the 
amount of MNC, which varied in our five expansions from 64*106 to 94*106 cells. The cells and beads 
were incubated for 30 minutes in refrigerator at 4 °C, the T lymphocytes could then be positively 
selected on a magnet. The positively selected cells were then placed in incubation medium, 
consisting of RPMI 1640-medium, complemented with 2mM L-glutamine (Sigma Aldrich Inc., St. 
Louis, Missouri) 100 IU/ml Penicillin G (antibiotic), 100 µg/ml Streptomycin (antibiotic), 0.25 µg/ml 
Amphotericin B (antifungal drug) (Invitrogen Corp., Carlsbad, California) and 10% pooled human 
serum (Department of Transfusion Medicine at Karolinska University Hospital, Huddinge). The 
different culture conditions and their concentrations of IL-2 and IL-7 are shown in table 2. Only the 
first of our five expansions had all fourteen conditions, the last four were expanded in conditions 










1 0 0 
2 0 20 
3 50 0 
4 50 20 
5 100 0 
6 100 20 
7 200 0 
8 200 20 
9 400 0 
10 400 20 
11 600 0 
12 600 20 
13 800 0 
14 800 20 
Table 2: Each culture condition with their respective concentrations of IL-2 and IL-7 that were used in the expansions. 
  
The cells were incubated at 37 °C with 5% CO2 and kept at concentrations ≤ 300.000 cells/ml 
throughout the expansion period. From day 0 through day 3 the cells did not proliferate enough to 
be diluted, though on day 4, 5 and 6 the cells were counted. Medium, IL-2 and IL-7 were refilled to 
keep stable concentrations. Day 7, the day of finalization, the cells were once again counted, washed 
twice on magnet (the cells and beads are at this point of time separated) and frozen in 10 % DMSO 
freezing medium at concentrations < 10.000.000 cells/ml.  
 
2.3. Cell Surface and Intracellular Staining for Flow Cytometry 
The day of fluorescence-activated cell sorting (FACS) analysis the cells were thawed and washed as 
described earlier. The cells were then equally distributed into wells of a 96-well cell culture plate 
where the antibodies for cell surface markers were added with staining buffer and PBS and incubated 
in refrigerator at 4 °C for 30 minutes before washing x2 and re-suspension in PBS.  
Annexin V/7-AAD staining was executed following the instructions from the manufacturer (BD 
Pharmingen). FACS was performed using the LSR II Flow Cytometer System (BD Biosciences, USA), 
and the data were analysed using the FlowJo software (Tree Star, Inc., Oregon, USA). 
 
2.4. Statistical Analysis 






3. RESULTS  
3.1. Fold Expansion by T Cells 
The protocol described was used in five expansions, with good and quite unambiguous results.  
The numbers of T cells in our expansions were at day 0, the first day of incubation, between 2.05*106 
and 3.85*106 cells. The T cells were incubated for 8 days (day 0-7), and expanded with an average 
fold expansion of 65.1 in all the conditions, and by 50.0 and 80.3 for the culture conditions with only 
IL-2 and IL-2 plus IL-7, respectively. When adding IL-7, the expansion was highest in culture condition 
6 and 8, with 100 and 200 IU/ml IL-2, respectively. IL-7 induced in average 62% increased fold 
expansion. Quite clear tendencies were observed, although no statistical significance could be 
demonstrated.  
 
Figure 1a: Average number of cells after an 8 day culture, comparison of each IL-2 concentration +/- IL-7. 
 
















Average numbers of cells at day 7 of 



























3.2. CD4+/CD8+-Ratio of Expanded T Cells 
The expanded cells had an average CD4+/CD8+-ratio of 2.56, with average ratios of 2.18 and 2.95 for 
culture conditions without and with IL-7, respectively. Although no significant differences, the 
average ratios for each culture condition are given in figure 2.  
 




-ratios for each culture condition of the expansions, standard deviations are shown in error 
bars. 
 
3.3. Degree of Differentiation in Expanded T Cells 
Based on the definitions of naïve cells, effector cells and memory cells above, the CD3+ cells could be 
grouped according to expression of CCR7 and/or CD45RO. Our data showed that most of the 
expanded CD3+ cells are of the central- and effector memory cell subsets (Tcm and Tem). Also a 
considerably amount of the expanded cells in culture condition 1, i.e. no IL-2 and no IL-7, were of the 
naïve subset (22.3%). It was an evident difference in memory subsets in culture conditions receiving 
IL-7 from those that did not. Most clearly seen in CD4+-cells, Tem cells were a bigger portion of the 
expanded cells in cultures with IL-7, and in cultures that only received IL-2, the proportion of cells of 
Tem and Tcm subsets were similar. These differences were not as evident among the CD8+ cells, but 
the differences can be seen in the overall CD3+ pool. The CD8+ portion of cells did however have 
larger quotas of naïve (Tn, CD45RO-CCR7+) and terminally differentiated (Ttde, CD45RO-CCR7-) cells 


















Figure 3a: Distribution of expanded CD3
+



















Conditions 1-12 with their respective IL-2 concentrations are shown the x-axis. 
 
 

























































































































































3.4. Expression of CD95 and Binding of 7-AAD and Annexin V by 
Expanded T Cells 
T cells expressing CD95 (FasR) can easily, by binding FasL, get a signal of apoptosis. CD95/FasR can be 
up-regulated by T cell activation, IL-2 and anti-CD3 [104-106], and is involved in activation-induced 
cell death (AICD) [107]. As could be expected, almost all of the expansions had 100% CD95+ cells. The 
lowest percentage of CD95+ cells was seen in culture condition 1 of the first of our five expansions 
where 97% of cells were CD95+. 
Annexin V is a protein that binds to phosphatidylserine, which is translocated from the inside of cell 
membranes to the outside upon initiation of apoptosis. We have therefore used this as a marker of 
early apoptosis. 7-AAD (Amino-Actinomycin D) binds strongly to DNA and cannot pass through intact 
cell membranes. It can therefore be used to identify cells that are dead; either by necrosis or late 
stage apoptosis where cell membrane integrity is lost.  
The expanded T cells were divided into live cells (Annexin V- 7-AAD-), apoptotic cells (Annexin V+) and 
dead cells, either by apoptosis or necrosis (Annexin V+ 7-AAD+). In most of the culture conditions 
there was a tendency to be more alive/viable cells in those receiving IL-7, and in all of the culture 
conditions there were in average most dead cells in those expanded with only IL-2. The only two 
culture conditions where live/viable cells were in average a majority, were culture conditions 6 and 8, 
both with IL-7 and 100 and 200 IU/ml IL-2 respectively (Fig. 4). These were also the same two culture 
conditions with the highest overall fold expansion (Fig. 1b). 
 
Figure 4: Percentages of expanded T cells that were alive, apoptotic and dead, classified from their binding of Annexin V 



















































We have only completed five expansions with this protocol, i.e. the 12 different culture conditions 
described. Due to this low number of expansions, it is difficult to prove any statistical significance of 
the data. Nevertheless, it seemed to be clear and uniform tendencies of our results. 
 
4.1. Fold Expansion 
The data of our expansions shows an advantageous effect of IL-7 on fold expansion. This coincides 
with data from a pilot project we executed earlier (data not shown) and also with data presented by 
Davis et al. in 2010 (ref. [108]), although there were some differences between the protocols used: 
they used an expansion period of 12-14 days, while ours were of 8 days, they operated with an IL-2 
concentration of 100 units/ml +/- 10 ng/ml IL-7, and kept a cell concentration of 1*106 cells/ml 
throughout the expansion period. Davis et al. demonstrated a significant difference in fold expansion.  
 
4.2. CD4+/CD8+-Ratio 
From our data we could suspect a higher CD4+/CD8+-ratio among cells expanded with IL-7 compared 
with IL-2 alone. This concurs with our pilot expansions that were performed some time ago (data not 
shown). Okas et al. (ref. [103]) demonstrated a skewing of CD4+/CD8+-ratio among in vitro expanded 
T cells compared to peripheral blood and non-expanded T cells. Mazur et al. showed in 2008 (ref. 
[64]) an inversion of CD4+/CD8+-ratio in expansions with IL-2 and CD3/CD28 co-stimulation. This 
suggests that expansions including IL-7 could decrease/inhibit this skewing or inversion of this ratio. 
 
4.3. Degree of Differentiation 
In our experiments there were mainly T cells of memory subsets (Tcm and Tem) among the expanded 
cells. This correlates well with the data from Okas et al. (ref. [103]) where naïve (Tn) and terminally 
differentiated effector (Ttde) T cells were not present at all after expansion. The absence of naïve 
cells could either be a result of lacking proliferation of these, or a differentiation of proliferating 
naïve cells into memory subsets. These cell subsets were not absolutely absent in our expansions 
however, especially among CD8+ T cells. In the study published by Davis et al. (ref. [108]) they 
grouped T cells in differentiation subsets based on other cell markers: “phenotypically naïve” cells 
were defined as CD45RA+CD62L+ and, in contrast to our expansions, they showed that these markers 
were expressed by most expanded T cells, with significant more among the IL-7 cultured T cells (73% 




differences in classification molecules make it difficult to compare subsets, since Davis et al. reported 
that the degree of expression of these molecules were nearly identical to non-expanded cord blood T 
cells, while data from Okas et al. showed that in non-expanded T cells less than half of the T cells 
were of a naïve phenotype.  
 
4.4. CD95 Expression and Quotas of Apoptotic and Dead Cells among 
Expanded Cells 
Almost all of the T cells expanded with our protocol expressed CD95/FasR. This could be expected 
from our culture conditions containing IL-2. This high expression can, in part, explain the high 
number of apoptotic and dead cells among our expanded T cells, through its involvement in AICD. 
Identification of apoptotic and dead cells were based on binding of Annexin V and 7-AAD as 
described. We could see a tendency towards beneficial effects from IL-7 on expanded T cell survival, 
as could Davis et al. [108] with demonstration of significantly more viable cells in cultures including 
IL-7 (71% versus 46%). They had in addition significantly higher numbers of apoptotic cells in absence 
of IL-7, in both CD4+ and CD8+ subsets. The latter results were based on expression of intracellular 
activated caspase-3. They also analyzed cells after freezing, thawing and resting in cytokine-free 
medium, where 53% and 57% of IL-2-only cells stained for 7-AAD and Annexin V, respectively, while 








From our results of five UCB T cell-expansions, it is difficult to promote changes in culture conditions, 
although our results were mostly uniform in showing the advantageous results of IL-7. The formerly 
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